Doseology Overhauls Leadership Amid Shares-for-Debt Settlement…

Event summary

Doseology appoints Kareem Baalbaki as interim CEO, CFO, and director, replacing Chris Jackson and Chris Cherry.
Jeremy Wright, CFO of Avant Brands, joins Doseology's board.
Company issues 75,268 shares at $0.18 each to settle $13,548.39 in consulting debt.
Baalbaki's background includes scaling Revive Superfoods from $10M to $150M in revenue.
Wright's experience spans TSX and Nasdaq listings, with roles at GTEC and Alpha Cognition.

The big picture

Doseology's leadership overhaul signals a strategic pivot toward operational efficiency and financial discipline. The appointments of Baalbaki and Wright suggest a focus on scaling production and refining capital structure, critical moves as the oral stimulant pouch market gains momentum. The shares-for-debt settlement underscores immediate liquidity pressures, while the new executives' track records hint at long-term growth ambitions.

What we're watching

Operational Scaling: How Baalbaki's CPG experience will address Doseology's growth challenges.
Financial Strategy: Whether Wright's capital-markets expertise can stabilize Doseology's balance sheet.
Market Positioning: The pace at which Doseology can capitalize on the expanding oral pouch category.